symbol,name,summary,currency,sector,industry_group,industry,exchange,market,country,state,city,zipcode,website,market_cap,isin,cusip,figi,composite_figi,shareclass_figi
015.F,"Aileron Therapeutics, Inc.","Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Watertown, Massachusetts.",EUR,Health Care,"Pharmaceuticals, Biotechnology & Life Sciences",Biotechnology,FRA,Frankfurt Stock Exchange,United States,MA,Watertown,2472,http://www.aileronrx.com,Micro Cap,,,,,
01P.F,"Medpace Holdings, Inc.","Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.",EUR,Health Care,"Pharmaceuticals, Biotechnology & Life Sciences",Biotechnology,FRA,Frankfurt Stock Exchange,United States,OH,Cincinnati,45227,http://www.medpace.com,Mid Cap,US58506Q1094,58506Q109,BBG00DLDCCQ1,BBG00DLDCCP2,BBG0065B7K40
04IC.F,InVivo Therapeutics Holdings Corp.,"InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). The company is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.",EUR,Health Care,"Pharmaceuticals, Biotechnology & Life Sciences",Biotechnology,FRA,Frankfurt Stock Exchange,United States,MA,Cambridge,2139,http://www.invivotherapeutics.com,Nano Cap,US46186M6057,46186M605,,,
04X.F,"Personalis, Inc.","Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. The company has partnership with Berry Genomics; Natera, Inc.; and MapKure, LLC. Personalis, Inc. was founded in 2011 and is headquartered in Menlo Park, California.",EUR,Health Care,"Pharmaceuticals, Biotechnology & Life Sciences",Biotechnology,FRA,Frankfurt Stock Exchange,United States,CA,Menlo Park,94025,http://www.personalis.com,Small Cap,GB0006825383,,BBG00PH0G7V8,BBG00PH0G7T1,BBG0027NWBS7
07X.F,"Annovis Bio, Inc.","Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.",EUR,Health Care,"Pharmaceuticals, Biotechnology & Life Sciences",Biotechnology,FRA,Frankfurt Stock Exchange,United States,PA,Berwyn,19312,http://www.annovisbio.com,Micro Cap,US03615A1088,03615A108,BBG00VYKPVS3,BBG00VYKPVR4,BBG00PN9XDJ4
